Evidence map›Paper›PMID 31141817›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2019

Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior.

Joshua D Gross, Shane W Kaski, Karl T Schmidt, Elizabeth S Cogan, Kristen M Boyt, Kim Wix, Adam B Schroer, Zoe A McElligott, David P Siderovski, Vincent Setola

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Genetic deletion ofJournal of psychopharmacology (Oxford, England) · 2020
    Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Joshua D GrossDepartment of Physiology & Pharmacology, 3048 HSN, West Virginia University Health Sciences Center, 64 Medical Center Drive, Morgantown, WV, 26508, USA.
Shane W KaskiDepartment of Physiology & Pharmacology, 3048 HSN, West Virginia University Health Sciences Center, 64 Medical Center Drive, Morgantown, WV, 26508, USA.
Karl T SchmidtBowles Center for Alcohol Studies and Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Elizabeth S CoganBowles Center for Alcohol Studies and Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Kristen M BoytBowles Center for Alcohol Studies and Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Kim WixDepartment of Physiology & Pharmacology, 3048 HSN, West Virginia University Health Sciences Center, 64 Medical Center Drive, Morgantown, WV, 26508, USA.
Adam B SchroerDepartment of Physiology & Pharmacology, 3048 HSN, West Virginia University Health Sciences Center, 64 Medical Center Drive, Morgantown, WV, 26508, USA.
Zoe A McElligottBowles Center for Alcohol Studies and Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
David P SiderovskiDepartment of Physiology & Pharmacology, 3048 HSN, West Virginia University Health Sciences Center, 64 Medical Center Drive, Morgantown, WV, 26508, USA. dsiderovski@gmail.com.
Vincent SetolaDepartment of Physiology & Pharmacology, 3048 HSN, West Virginia University Health Sciences Center, 64 Medical Center Drive, Morgantown, WV, 26508, USA.
West Virginia University · USUniversity of North Carolina at Chapel Hill · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Laura F. Gibson · 2012 to 2026
$81.0M
UNC ARC Information/Dissemination CoreP60AA011605 · NIAAA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Clyde W Hodge · 2003 to 2026
$46.3M
Supplement to Molecular and Cellular Studies on Alcohol's ActionsT32AA007573 · NIAAA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FULTON T CREWS, Thomas L. Kash · 1997 to 2026
$9.3M
Probing Ethanol Induced Acceleration of Hindbrain and Amygdalar Pathology in an Alzheimer’s Disease ModelU01AA020911 · NIAAA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Thomas L. Kash, Zoe Anastasia McElligott · 2012 to 2026
$5.8M
Research Training Program in the Behavioral and Biomedical SciencesT32GM081741 · NIGMS · WEST VIRGINIA UNIVERSITY · PI BERREBI, ALBERT S, SIMPKINS, JAMES W. · 2008 to 2018
$2.1M
Core 1: Brain Circuit Validation CoreU24AA025475 · NIAAA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KASH, THOMAS L. · 2017 to 2021
$1.1M
Deconstructing the role of central nucleus of the amygdala neurotensin neurons in alcohol reward and intoxicationK01AA023555 · NIAAA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MCELLIGOTT, ZOE ANASTASIA · 2015 to 2019
$675k
Role of Regulator of G-protein Signaling-12 (RGS12) in morphine modulated behaviorF30DA044711 · NIDA · WEST VIRGINIA UNIVERSITY · PI KASKI, SHANE WEST · 2018 to 2020
$147k
The role of RGS12 in the action of amphetamine and related drugs of abuseF31DA043331 · NIDA · WEST VIRGINIA UNIVERSITY · PI GROSS, JOSHUA D · 2017 to 2018
$88k
NIAAA NIH HHS K01 AA023555NIAAA NIH HHS P60 AA011605NIAAA NIH HHS T32 AA007573NIAAA NIH HHS U01 AA020911NIAAA NIH HHS U24 AA025475NIDA NIH HHS F30 DA044711NIDA NIH HHS F31 DA043331NIGMS NIH HHS T32 GM081741NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

Kappa opioid receptor (KOR) agonists show promise in ameliorating disorders, such as addiction and chronic pain, but are limited by dysphoric and aversive side effects. Clinically beneficial effects of KOR agonists (e.g., analgesia) are predominantly mediated by heterotrimeric G protein signaling, whereas β-arrestin signaling is considered central to their detrimental side effects (e.g., dysphoria/aversion). Here we show that Regulator of G protein Signaling-12 (RGS12), via independent signaling mechanisms, simultaneously attenuates G protein signaling and augments β-arrestin signaling downstream of KOR, exhibiting considerable selectivity in its actions for KOR over other opioid receptors. We previously reported that RGS12-null mice exhibit increased dopamine transporter-mediated dopamine (DA) uptake in the ventral (vSTR), but not dorsal striatum (dSTR), as well as reduced psychostimulant-induced hyperlocomotion; in the current study, we found that these phenotypes are reversed following KOR antagonism. Fast-scan cyclic voltammetry studies of dopamine (DA) release and reuptake suggest that striatal disruptions to KOR-dependent DAergic neurotransmission in RGS12-null mice are restricted to the nucleus accumbens. In both ventral striatal tissue and transfected cells, RGS12 and KOR are seen to interact within a protein complex. Ventral striatal-specific increases in KOR levels and KOR-induced G protein activation are seen in RGS12-null mice, as well as enhanced sensitivity to KOR agonist-induced hypolocomotion and analgesia-G protein signaling-dependent behaviors; a ventral striatal-specific increase in KOR levels was also observed in β-arrestin-2-deficient mice, highlighting the importance of β-arrestin signaling to establishing steady-state KOR levels in this particular brain region. Conversely, RGS12-null mice exhibited attenuated KOR-induced conditioned place aversion (considered a β-arrestin signaling-dependent behavior), consistent with the augmented KOR-mediated β-arrestin signaling seen upon RGS12 over-expression. Collectively, our findings highlight a role for RGS12 as a novel, differential regulator of both G protein-dependent and -independent signaling downstream of KOR activation.

Indexed as

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAnimalsAvoidance LearningBehavior, Animalbeta-ArrestinsDopamineEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Enkephalin, Leucine-2-AlanineFemaleLocomotionMaleMiceMice, KnockoutNucleus AccumbensReceptors, Opioid, kappaRGS Proteins3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomerbeta-ArrestinsDopamineEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Enkephalin, Leucine-2-AlanineReceptors, Opioid, kappaRGS12 protein, mouseRGS Proteins

Identifiers

PMID31141817
PMCPMC6785087
OpenAlexW2946984001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.